We exist to provide better treatment options WA patients with bloods cancers through increasing access to clinical trials.

Clinical trials are the most important tool we have for improving the survival of patients with cancer. You should discuss with your doctor whether a clinical trial is available and appropriate for you.

NHL33

NHL33 An ALLG Window Study of Acalabrutinib plus Rituximab followed by Cytarabine, Oxaliplatin, Dexamethasone and Rutixumab (R-DHAOx) + Autologous Stem Cell Transplant (ASCT) in newly diagnosed fit Mantle Cell Lymphoma…
Read More

DREAMM 3

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin…
Read More

ITHACA

A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone…
Read More

SYMPATICO

Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
Read More

GCT-3013-01

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Read More

BGB-3111-113

A Drug–Drug Interaction Study of Zanubrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancies
Read More

MALT-1

A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of…
Read More

UNITY-NHL

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab +…
Read More

TG-1701

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of TG-1701, an Irreversible Bruton’s Tyrosine Kinase Inhibitor, in Patients…
Read More

GO29781

An open-label, multicenter, phase I/IB trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A as…
Read More

FORMA

A Phase 1/2 study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of FT-2102 with or without azacitidine…
Read More

PLIMATH

A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma (PLIMATH)
Read More

GMI-1271-301

A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy…
Read More

DREAMM6

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide…
Read More

ACE-CL-311

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in…
Read More

LOXO-BTK-18001

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with Chronic lymphocytic leukemia,…
Read More

TG-1801

A Phase 1 First-in-Human Study of Bispecific Antibody TG-1801 in Subjects With B-Cell Lymphoma
Read More

CPI-818-001

This is a Phase 1/1b, open-label, first in human study of CPI-818 (an oral interleukin-2-inducible tyrosine kinase…
Read More

TREBL-1 (NHL31)

An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab, Valaciclovir and 3rd Party EBV specific T…
Read More

LEVERAGE

Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment Naïve Follicular Lymphoma
Read More

ASSURE

ASSURE is a Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib in Subjects with Chronic Lymphocytic Leukaemia.
Read More

BGB-11417-101

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature…
Read More

AFM13

Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides…
Read More

Clinical Trial FAQ’s

Menu